AcquisitionsJul 16, 2026, 05:21 PM
Jasper Therapeutics Acquires Kira Pharma; Secures $132M Private Placement
AI Summary
Jasper Therapeutics, Inc. announced the completion of its acquisition of Kira Pharmaceuticals in an all-stock transaction. Concurrently, the company secured a private placement financing for gross proceeds of $132 million. Additionally, Kira out-licensed two assets, KP-301 and KP-402, to Mirador Therapeutics for a $12 million upfront payment and potential milestones. These transactions are expected to fund the combined company's operations through the second half of 2028, supporting the advancement of a consolidated pipeline of immunologically-driven disorder therapies.
Key Highlights
- Completed acquisition of Kira Pharmaceuticals in an all-stock transaction.
- Secured $132 million in gross proceeds from a concurrent private placement financing.
- Kira out-licensed KP-301 and KP-402 to Mirador Therapeutics for $12 million upfront.
- Combined company operations expected to be funded through the second half of 2028.
- Post-transaction ownership: Jasper equityholders ~6.68%, Kira equityholders ~49.86%, investors ~43.46%.
- Total shares outstanding post-transaction will be approximately 653.6 million.
- Pipeline includes KP-104 (Phase 2/3 ready), Briquilimab (late-stage), and KP-701 (preclinical).
Price Impact
More from JSPR